Chemotherapy-induced Nausea and Vomiting
Conditions
Brief summary
Chemotherapy-induced nausea and vomiting continues to be a significant problem in children and adolescents. Standard antiemetic therapy, including a 5-HT3 antagonist, aprepitant, and a corticosteroid, achieves complete control in less than 50% of patients. Studies have shown that the addition of large doses of olanzapine improves control, including in children and adolescents. However, olanzapine has not yet been included in standard recommendations in the pediatric population. Studies in adults indicate that the dose of the drug can be halved without loss of effectiveness and with a decrease in toxicity. This open-label, randomized, phase III trial evaluates the efficacy and safety of adding low-dose olanzapine to standard prevention of nausea and vomiting induced by highly emetogenic chemotherapy in children and adolescents.
Detailed description
After signing informed consent, eligible patients are randomized with stratification (previously received or not received high emetogenic therapy; regimens with and without cisplatin) to receive the first cycle of highly emetogenic chemotherapy with standard prophylaxis (5-HT3 receptor antagonist, dexamethasone, aprepitant) with or without addition of 0.07 mg/kg olanzapine (rounded to multiples of 2.5 mg, maximum 5 mg). During chemotherapy and 120 hours after its completion, patients are assessed for the presence and absence, as well as the severity of CINV, the need for rescue therapy, and the development of adverse events. In the future, patients undergo a similar course of highly emetogenic chemotherapy with a change in the antiemetic prophylaxis option - crossover (patients who received an olanzapine regimen as antiemetic prophylaxis after the first cycle of chemotherapy receive treatment without it, patients who received prophylaxis without olanzapine receive a second cycle of therapy with olanzapine). After this cycle, the presence and absence, as well as the severity of CINV, the need for salvage therapy, the development of adverse events are assessed and, additionally, at the end of the cycle, patients are asked about the preferred option for further antiemetic prophylaxis (the regimen with olanzapine, no olanzapine, or no preferences).
Interventions
DRUGAprepitant
Aprepitant will be administered based on body weight: body weight 30-40 kg: days 1-3 - 80 mg orally; body weight \> 40 kg: day 1 - 125 mg orally, days 2, 3 - 80 mg orally
DRUGOndansetron
Ondnsetron will be administered at a dose of 0.15 mg/kg IV/PO every 8 hours on the day(s) of chemotherapy and 3 days after completion of chemotherapy
DRUGDexamethasone
Dexamethasone will be administered at a dose of 5 mg/m2 intravenously/orally once on the day(s) of chemotherapy and 3 days after completion of chemotherapy;
DRUGOlanzapine
Olanzapine will be administered at a dose of 0.07 mg/kg orally on the day(s) of chemotherapy and 3 days after completion of chemotherapy (rounded up to the maximum multiple of 2.5 mg, maximum daily dose of 5 mg).
Sponsors
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
1. Age from 5 to 18 years. 2. Body weight ≥ 30 kg. 3. Confirmed diagnosis of malignancy. 4. Planned at least 2 cycles of highly emetogenic chemotherapy according to the Pediatric Ontario Cancer Group (POGO) emetogenicity classification. 5. ECOG status \< 3. 6. Adequate function of internal organs (bilirubin \< 1.5 upper limit of normal (ULN), ALT and AST \<2.5 ULN, creatinine \< 1.5 ULN). 7. Ability to swallow study drug. 8. The presence of a written voluntary informed consent of the patient and / or his legal representative.
Exclusion criteria
1. Treatment with olanzapine or another antipsychotic drug within the last 30 days. 2. Planned use of antibiotics from the group of fluoroquinolones or other drugs that have drug interactions with olanzapine and other drugs used in the study (amifostin, citalopram, CYP1A2 inducers or inhibitors). 3. The presence of intensive CINV against the background of a previous similar cycle of chemotherapy, which does not allow prescribing standard antiemetic prophylaxis upon inclusion in the study. 4. The presence of a convulsive syndrome. 5. Hypersensitivity to olanzapine or other drugs used in the study. 6. Uncontrolled arterial hypertension or cardiovascular disorders, uncontrolled diabetes mellitus, or other diseases and conditions that, in the opinion of the physician, preclude study therapy. 7. The presence of other factors (other than ongoing highly emetogenic therapy) that can cause the development of CINV (radiotherapy to the abdominal cavity or pelvis 1 week or less before inclusion in the study, obstruction of the gastrointestinal tract, uncontrolled intracranial hypertension, etc.). 8. Severe CINV of any intensity 24 hours or less before the first dose of chemotherapy. 9. Pregnancy or breastfeeding. 10. Planned use of systemic glucocorticosteroids at the time of inclusion in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Complete control of vomiting | up to 21 days | proportion of patients who did not have episodes of vomiting and/or use of additional antiemetic drugs (rescue therapy) during the chemotherapy cycle and within 120 hours after its completion |
| Patient preference | up to 42 days | Proportion of patients who, after crossover, chose to continue treatment with an experimental regimen including olanzapine |
| Adverce events | up to 42 days | Percentage of patients with grade 3-4 adverse events according to CTCAE v. 5.0. \[Time frame: day(s) of chemotherapy administration and 120 hours after chemotherapy administration\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete control of acute vomiting | up to 21 days | Proportion of patients who did not have episodes of vomiting and/or use of additional antiemetic drugs (rescue therapy) during the chemotherapy cycle and within 24 hours after its completion |
| Complete control of chemotherapy-induced nausea and vomiting (CINV) | up to 21 days | Proportion of patients who did not experience nausea (PeNAT score 1) and/or vomiting and/or use of additional antiemetics (rescue therapy) during the chemotherapy cycle and within 120 hours after its completion |
Countries
Russia
Contacts
Primary ContactNikolay Zhukov, MD,PhD
Outcome results
None listed